Haphazard reporting of deaths in clinical trials: A review of cases of ClinicalTrials.gov records and matched publications-a cross-sectional study

BMJ Open

Volumn 3, Issue 1, 2013, Pages

  Earley, Amy ^a   Lau, Joseph ^b   Uhlig, Katrin ^a,c  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BROWN UNIVERSITY   (United States)

^c TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE;

ADVERSE OUTCOME; AMYOTROPHIC LATERAL SCLEROSIS; CANCER MORTALITY; CANCER SURVIVAL; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL (TOPIC); CROSS-SECTIONAL STUDY; FOLLOW UP; HUMAN; LUNG CANCER; METASTASIS; MORTALITY; MULTIPLE MYELOMA; NON INSULIN DEPENDENT DIABETES MELLITUS; OVERALL SURVIVAL; PENIS CANCER; PROSTATE CANCER; PUBLICATION; REVIEW;

EID: 84873449661     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2012-001963     Document Type: Review

References (19)

1. Chou R, Helfand M. Challenges in systematic reviews that assess treatment harms. Ann Intern Med 2005;142(12 Pt 2):1090-9. (Pubitemid 40847712)
2. Ioannidis JP, Lau J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA 2001;285:437-43. (Pubitemid 32097262)
3. Food and Drug Administration. Code of Federal Regulations Title 21. 21 CFR 312.33 (b) (3)-Annual Reports. 2012. Ref Type: Bill/Resolution
4. Food and Drug Administration. Investigational new drug safety reporting requirements for human drug and biological products and safety reporting requirements for bioavailability and bioequivalence studies in humans. Final rule. Fed Regist 2010;75:59935-63.
5. Sherman RB, Woodcock J, Norden J, et al. New FDA regulation to improve safety reporting in clinical trials. N Engl J Med 2011;365:3-5.
6. Food and Drug Administration. Code of Federal Regulations Title 21. 21 CFR 312.32 (c) (1) (i) (C)-IND safety reporting. 2012. Ref Type: Bill/Resolution
7. Zarin DA, Tse T, Williams RJ, et al. The ClinicalTrials.gov results database-update and key issues. N Engl J Med 2011;364:852-60.
8. Food and Drug Administration Amendments Act. U. S. Public Law 110-85. 2012. Ref Type: Bill/Resolution
9. Tse T, Williams RJ, Zarin DA. Reporting 'basic results' in ClinicalTrials.gov. Chest 2009;136:295-303.
10. Food and Drug Administration Amendments Act. U. S. Public Law 110-95. 2007. Ref Type: Bill/Resolution
11. ClinicalTrials.gov. ClinicalTrials.gov 'Basic Results' Data Element Definitions. 2012. http://prsinfo.clinicaltrials.gov/results-definitions. html#AdverseEvents (accessed 26 Jun. 2012). Ref Type: Online Source
12. Cato A. Premarketing adverse drug experiences: data management procedures. Unexpected death occurring early in clinical trials.Drug Inf J 1987;21:3-7. (Pubitemid 17065994)
13. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med 2010;152:726-32.
14. Ioannidis JP, Evans SJ, Gotzsche PC, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med 2004;141:781-8. (Pubitemid 39524916)
15. Mansi BA, Clark J, David FS, et al. Ten recommendations for closing the credibility gap in reporting industry-sponsored clinical research: a joint journal and pharmaceutical industry perspective. Mayo Clin Proc 2012;87:424-9.
16. Prayle AP, Hurley MN, Smyth AR. Compliance with mandatory reporting of clinical trial results on ClinicalTrials.gov: cross sectional study. BMJ 2012;344:d7373.
17. Ross JS, Tse T, Zarin DA, et al. Publication of NIH funded trials registered in ClinicalTrials.gov: cross sectional analysis. BMJ 2012;344:d7292.
18. Drazen JM. COX-2 inhibitors-a lesson in unexpected problems. N Engl J Med 2005;352:1131-2. (Pubitemid 40365355)
19. Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 2010;170:1191-201.